PMID: 11328299May 1, 2001Paper

Treatment of refractory T-cell malignancies using gemcitabine

British Journal of Haematology
S SallahN P Nguyen

Abstract

We have treated 10 patients with relapsed or refractory T-cell malignancies using gemcitabine. The drug was administered intravenously over 30 min at a dose of 1200 mg/m2 on d 1, 8 and 15 of each 28-d cycle. The mean age of the patients was 62 years and the mean number of administered cycles was three. Of the 10 patients, two achieved a complete response and four a partial response, for an overall response rate of 60% (95% confidence interval 20--35%). The toxicity of chemotherapy was mild and manageable in all patients. These encouraging results warrant further investigation of gemcitabine either as a single agent or in combination regimens as early salvage treatment for patients with refractory T-cell haematological neoplasms.

References

Oct 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B CoiffierJ P Magaud
Jul 1, 1996·The American Journal of Cardiology·J E EichnerP C Comp
Jul 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R PawsonD Catovsky
Apr 16, 1998·Annals of Hematology·I Lorand-MetzeF J Aranha
Jan 22, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A D HoR Zittoun
Jul 13, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P L ZinzaniS Tura
Jul 13, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A SantoroV Diehl

❮ Previous
Next ❯

Citations

Nov 26, 2005·Cancer Chemotherapy and Pharmacology·Jong Gwang KimChang-Hak Sohn
Apr 30, 2004·Current Treatment Options in Oncology·Jeanette Lundin, Anders Osterborg
Oct 1, 2008·Current Hematologic Malignancy Reports·Hilary M O'Leary, Kerry J Savage
Sep 14, 2011·Current Hematologic Malignancy Reports·Michal K Sieniawski, Anne L Lennard
Aug 19, 2008·Current Oncology Reports·Hilary M O'Leary, Kerry J Savage
Jul 26, 2012·Blood Cancer Journal·N K El-MallawanyM S Cairo
Aug 18, 2004·Current Opinion in Oncology·Francine Foss
Sep 26, 2012·The Cancer Journal·Kelley V Foyil, Nancy L Bartlett
Dec 9, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kieron DunleavySusan E Bates
Dec 21, 2012·Future Oncology·Terri ParkerFrancine Foss
Dec 29, 2010·Advances in Hematology·Y Y Hwang, R H S Liang
Feb 16, 2013·Expert Opinion on Pharmacotherapy·Alexei Shimanovsky, Constantin A Dasanu
Oct 18, 2014·Expert Opinion on Investigational Drugs·Doraid Alrifai, Ruth Pettengell
Dec 18, 2012·The American Journal of the Medical Sciences·Hongyu ZhangLiping Lie
Jan 29, 2014·Seminars in Hematology·Nishitha M Reddy, Andrew M Evens
Jan 27, 2016·Critical Reviews in Oncology/hematology·Pier Luigi ZinzaniStefano Pileri
Apr 3, 2010·Seminars in Hematology·Owen A O'Connor
Feb 13, 2010·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Gerhard SissolakPeter Jacobs
Dec 17, 2008·Clinical Lymphoma & Myeloma·Lori J Rosenstein, Brian K Link
Oct 29, 2008·Hematology/oncology Clinics of North America·Julie M Vose
Nov 19, 2002·Clinical Lymphoma·Ian ChauDavid Cunningham
Aug 2, 2006·Clinical Lymphoma & Myeloma·Madeleine DuvicNarin Apisarnthanarax
Jul 2, 2005·Clinical Lymphoma·ZuoMing HuangFrancine Foss
May 22, 2007·Blood Reviews·Kerry J Savage
Mar 10, 2016·Asia-Pacific Journal of Clinical Oncology·Jae-Cheol JoUNKNOWN CoOperative Study Group A for Hematology (COSAH)
Jan 2, 2007·Cancer Letters·Amit W Panwalkar, James O Armitage
Jun 30, 2005·International Journal of Dermatology·Rana Yavuzer AnadoluUmit Türsen
Jan 20, 2007·British Journal of Haematology·Nam H DangLuis Fayad
Apr 13, 2011·British Journal of Haematology·Claire E DeardenUNKNOWN British Committee for Standards in Haematology
Mar 22, 2006·Seminars in Hematology·Claire E Dearden
Jan 9, 2004·Hematology/oncology Clinics of North America·Claire E Dearden, Francine M Foss
Sep 10, 2014·Cancer Treatment Reviews·Bertrand CoiffierPier Luigi Zinzani

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.